Loading clinical trials...
Loading clinical trials...
A Phase II Study of VEGF Blockade With Bevacizumab Combined With Autologous Tumor/Dendritic Cell Vaccine (DC Vaccine), Interleukin-2 (IL-2) and Interferon-α-2b (IFNα-2b) in Patients With Metastatic Renal Cell Carcinoma (RCC)
Conditions
Interventions
DC vaccine
Bevacizumab
+2 more
Locations
1
United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Start Date
February 1, 2009
Primary Completion Date
January 1, 2013
Completion Date
January 1, 2013
Last Updated
December 1, 2015
NCT06391099
NCT07227415
NCT06835972
NCT07175480
NCT05700461
NCT05122546
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions